secwatch.observer — SEC 8-K summary
======================================

Issuer:     Natera, Inc. (NTRA)
CIK:        0001604821
Form:       8-K
Filed at:   2022-02-24T23:59:59+00:00
Accession:  0001104659-22-026592
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Natera Q4 revenue $173M (+54% YoY); net loss widens to $140.6M; FY 2022 guidance $770-790M
--------------------------------------------------------------------------------

- Q4 2021 revenue $173.0M (+53.9% YoY); full year 2021 revenue $625.5M (+60% YoY), exceeding prior guidance.
- Q4 net loss $140.6M ($1.48/share) vs $76.4M loss ($0.89/share) in Q4 2020; FY 2021 net loss $471.7M ($5.21/share).
- Processed ~438,800 tests in Q4 (+48.7% YoY); full year ~1,570,000 tests processed.
- FY 2022 guidance: revenue $770M-$790M; gross margin ~46%-48%; SG&A $560M-$590M; R&D $340M-$360M; net cash consumption $370M-$400M.
- Received CMS coverage for Signatera pan-cancer monitoring; presented positive data from Trifecta and CIRCULATE-Japan studies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604821/000110465922026592/0001104659-22-026592-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604821/000110465922026592/tm227574d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-026592

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer